The Centers for Medicare & Medicaid Services announced that starting November 12, 2020, Medicare beneficiaries can receive coverage of monoclonal antibodies to treat coronavirus disease 2019 (COVID-19) with no cost-sharing during the public health emergency (PHE). CMS’ coverage of monoclonal antibody infusions applies to bamlanivimab, which received an emergency use authorization (EUA) from the U.S.…
Are you a Member of NAHC?
Become a member or sign in and read full NAHC Report articles at your leisure. Membership is affordable even if you're a small business and it comes with a lot of other benefits.